$12.01
+1.57 (+15.04%)
Open$10.51
Previous Close$10.44
Day High$12.51
Day Low$10.41
52W High$26.97
52W Low$14.78
Volume—
Avg Volume287.0K
Market Cap262.06M
P/E Ratio21.87
EPS$0.94
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+130.3% upside
Current
$12.01
$12.01
Target
$27.66
$27.66
$15.31
$27.66 avg
$30.74
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 57.99M | 51.60M | 54.22M |
| Net Income | 180.8K | 210.8K | 183.8K |
| Profit Margin | 0.3% | 0.4% | 0.3% |
| EBITDA | 390.2K | 358.0K | 370.7K |
| Free Cash Flow | 84.1K | 101.4K | 117.1K |
| Rev Growth | +8.6% | +24.1% | +21.6% |
| Debt/Equity | 0.52 | 0.47 | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |